142247-37-8

Upstream product

• 64-17-5 ethanol 
• 24424-99-5 di-tert-butyl dicarbonate 
• 75-36-5 acetyl chloride 
• 158602-19-8 Ethyl 4-(N-BOC-piperidin-4-yl)crotonate 
• 142247-36-7 tert-butyl (E)-4-(4-ethoxy-4-oxobut-2-en-1-yl)piperidine-1-carboxylate 
• 105-53-3 diethyl malonate 
• 89151-45-1 tert-butyl-4-(2-(tosyloxy)ethyl)piperidine-1-carboxylate 

Downstream Products

• 142247-38-9 4-[1-(tert-butoxycarbonyl)piperidin-4-yl]butanoic acid 
• 91370-63-7 ethyl 4-(piperidin-4-yl)butyrate 

Relevant academic research and scientific papers

Novel ketooxazole based inhibitors of fatty acid amide hydrolase (FAAH)

Efforts to improve the properties of the well studied ketooxazole FAAH inhibitor OL-135 resulted in the discovery of a novel propylpiperidine series of FAAH inhibitors that has a modular design and superior properties to OL-135. The efficacy of one of the

Reactions between weinreb amides and 2-magnesiated oxazoles: A simple and efficient preparation of 2-acyl oxazoles

(Chemical Equation Presented) Treatment of oxazole or 5-aryl oxazoles with i-PrMgCl smoothly generates the corresponding 2-Grignard reagents, which react with Weinreb amides to provide exclusively 2-acyl oxazole products.

2-KETO-OXAZOLES AS MODULATORS OF FATTY ACID AMIDE HYDROLASE

Certain 2-keto-oxazole compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolas

AZAARENE DERIVATIVES

A compound represented by the general formula: wherein X1 represents a nitrogen atom or a group represented by the formula -CR10=; X2 represents a nitrogen atom or a group represented by the formula -CR11=; Y represents an oxygen atom or the like; R1 represents a C1-6 alkoxy group, an optionally substituted C6-10 aryloxy group, a group represented by the formula -NR12aR12b or the like; R2 represents a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like; R3, R4, R5, R6, R7, R8, R10 and R11 each independently represent a hydrogen atom, a halogen atom, an optionally substituted C1-6 alkyl group, or the like; R9 represents a group represented by the formula -NR16aR16b or the like; and R12a, R12b, R16a and R16b each independently represent a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like, a salt thereof, or a hydrate of the foregoing.

Lactams as selective factor Xa inhibitors

Novel lactams, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds of Formula I below: are useful in vitro or in vivo for preventing or treating coagulation disorders.

Dipiperidine derivatives

The present invention relates to an novel dipiperidine derivative represented by formula (1), or a pharmaceutically acceptable salt thereof; STR1 wherein R1 represents a hydrogen atom or a lower alkyl group; Y represents a single bond or an oxygen atom; n represents 1, 2 or 3; W represents a methylene group or an oxygen atom; R2 represents a hydrogen atom or a carboxyl modifying group which can be eliminated in vivo; X1 and X3 are the same or different and each represents a hydrogen atom or a lower alkyl group. This compound is useful as platelet aggregation inhibitors, cancer metastasis inhibitors, wound remedies or bone resorption inhibitors.

Fibrinogen receptor antagonists

Fibrinogen receptor antagonists of the formula: STR1 are disclosed for use in inhibiting the binding of fibrinogen to blood platelets and for inhibiting the aggregation of blood platelets.

Fibrinogen receptor antagonists

The present invention comprises fibrinogen receptor antagonist compounds, compositions containing them and methods for using them to inhibit fibrinogen binding to blood platelets. Compounds of the invention have the following formula STR1 wherein Z is STR

Fibrinogen receptor antagonists for inhibiting aggregation of blood platelets

Fibrinogen receptor antagonists of the formula: STR1 are disclosed for use in inhibiting the binding of fibrinogen to blood platelets and for inhibiting the aggregation of blood platelets.

Fibrinogen receptor antagonists

Fibrinogen receptor antagonists of the formula: STR1 are disclosed for use in inhibiting the binding of fibrinogen to blood platelets and for inhibiting the aggregation of blood platelets.